Shares of Truth Social merger partner fall after Trump’s candidates underwhelm in midterm elections

Shares of Truth Social merger partner fall after Trump’s candidates underwhelm in midterm elections


This photo illustration shows an image of former President Donald Trump next to a phone screen that is displaying the Truth Social app, in Washington, DC, on February 21, 2022.

Stefani Reynolds | AFP | Getty Images

Shares of the blank check company set to take Trump Media and its Truth Social platform public fell sharply Wednesday after candidates endorsed by the former president disappointed in high-profile midterm election races.

Digital World Acquisition Corp.‘s shares fell more than 16% Wednesday morning.

In Pennsylvania, Trump-endorsed Senate candidate Dr. Mehmet Oz lost to Democratic Lt. Gov. John Fetterman, NBC News reported, costing the Republican party a Senate seat. In Michigan, Tudor Dixon lost a gubernatorial race and Kristina Karamo lost her bid to be secretary of state. Both were supported by Trump.

The weekend leading into the election, Trump held huge rallies where he read off a list of Republican candidates. He also helped to raise hundreds of millions of dollars for Republican candidates in high-profile Senate campaign.

The rallies also served as a platform for Trump to seemingly hone a speech that sounded like his own bid for the 2024 presidential campaign. On Monday, shares of DWAC soared at Trump’s hinting of another presidential run.

Another presidential run could drive traffic to Trump’s Truth Social platform, as the ex-president has agreed to post exclusively on the social media platform for eight hours before posting it anywhere else.

Still, DWAC’s shares are trading sharply down so far this year as the special purpose acquisition company faces financial and legal challenges as it seeks to merge with Trump Media and and Technology Group, the parent company of Truth Social.

DWAC has been working to secure enough shareholder support to extend the deadline for the merger with Trump Media until Sept. 2023, with the vote being pushed back multiple times. It will take place again on Nov. 22.

The merger also faces a criminal probe into possible securities violations over discussions that took place between DWAC and Trump Media prior to the deal announcement.

The delays have prompted at least $138 million of $1 billion in investments to be pulled from DWAC. The ex-president himself has also suggested the SPAC merger might not go through. At an October rally in Michigan, Trump told supporters if the financing didn’t come through he would take it private.

–CNBC’s Jack Stebbins contributed to this article.



Source

CDC says there are no U.S. hantavirus cases currently, 41 people being monitored
Business

CDC says there are no U.S. hantavirus cases currently, 41 people being monitored

In this photo illustration Hantavirus samples are seen in Ankara, Turkiye on May 6, 2026. Arman Onal | Anadolu | Getty Images The U.S. Centers for Disease Control and Prevention said there are no hantavirus cases in the country as of Thursday, as it monitors 41 people for the virus. The agency said the risk […]

Read More
These three artworks could sell for 0 million each next week as May auctions begin
Business

These three artworks could sell for $100 million each next week as May auctions begin

A large-scale Jackson Pollock drip painting titled, “Number 7A, 1948.” Crystal Lau | CNBC A version of this article first appeared in CNBC’s Inside Wealth newsletter with Robert Frank, a weekly guide to the high-net-worth investor and consumer. Sign up to receive future editions, straight to your inbox. Nearly $2 billion worth of art will come up […]

Read More
Biogen advances Alzheimer’s drug to late-stage trial despite disappointing data
Business

Biogen advances Alzheimer’s drug to late-stage trial despite disappointing data

A Biogen facility in Cambridge, Massachusetts. Brian Snyder | Reuters Biogen plans to advance an experimental drug for Alzheimer’s disease to late-stage testing despite disappointing mid-stage trial data, the company said Thursday. Biogen said its experimental drug that targets tau, a protein associated with the memory-robbing disease, failed to show better responses at higher doses. […]

Read More